SCM
Silverarc Capital Management Portfolio holdings
AUM
$489M
This Quarter Return
+55.66%
1 Year Return
+71.55%
3 Year Return
+1,109.63%
5 Year Return
–
10 Year Return
–
AUM
$296M
AUM Growth
+$296M
(+33%)
Cap. Flow
+$55.4M
Cap. Flow
% of AUM
18.69%
Top 10 Holdings %
Top 10 Hldgs %
46.59%
Holding
90
New
21
Increased
29
Reduced
18
Closed
11
Top Buys
| 1 |
IMGN
Immunogen Inc
IMGN
|
$24M |
| 2 |
MORF
Morphic Holding, Inc. Common Stock
MORF
|
$11.5M |
| 3 |
Krystal Biotech
KRYS
|
$9.97M |
| 4 |
MoonLake Immunotherapeutics
MLTX
|
$4.81M |
| 5 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$4.67M |
Top Sells
| 1 |
BLU
BELLUS Health Inc.
BLU
|
$7.2M |
| 2 |
Nuvalent
NUVL
|
$7.02M |
| 3 |
Pharvaris
PHVS
|
$5.44M |
| 4 |
Regeneron Pharmaceuticals
REGN
|
$4.11M |
| 5 |
Immatics
IMTX
|
$2.9M |
Sector Composition
| 1 | Healthcare | 99.91% |
| 2 | Consumer Staples | 0.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Xenon Pharmaceuticals
XENE
$2.98B
| $3.84M | 1.19% |
99,756
+3,113
| +3% | +$120K |
|
27
Olema Pharmaceuticals
OLMA
$375M
| $3.53M | 1.09% |
+390,466
| New | +$3.53M |
|
28
Sarepta Therapeutics
SRPT
$1.78B
| $3.42M | 1.06% |
29,860
+20,590
| +222% | +$2.36M |
|
29
Prothena Corp
PRTA
$441M
| $3.39M | 1.05% |
+49,721
| New | +$3.39M |
|
|
MRTX
30
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $3.3M | 1.02% |
+91,213
| New | +$3.3M |
|
31
Mersana Therapeutics
MRSN
$36.5M
| $3.29M | 1.02% |
1,000,000
+459,941
| +85% | +$1.51M |
|
32
Insmed
INSM
$28.8B
| $3.05M | 0.94% |
144,464
+670
| +0.5% | +$14.1K |
|
|
33
Pharvaris
PHVS
$1.39B
| $3.03M | 0.94% |
200,000
-359,387
| -64% | -$5.44M |
|
34
ANI Pharmaceuticals
ANIP
$2.03B
| $2.91M | 0.9% |
+54,041
| New | +$2.91M |
|
35
Phathom Pharmaceuticals
PHAT
$864M
| $2.86M | 0.89% |
200,000
| – | – |
|
36
Cerus
CERS
$251M
| $2.85M | 0.88% |
1,158,265
+5,363
| +0.5% | +$13.2K |
|
37
Mirum Pharmaceuticals
MIRM
$3.71B
| $2.75M | 0.85% |
106,375
+436
| +0.4% | +$11.3K |
|
38
Aclaris Therapeutics
ACRS
$209M
| $2.27M | 0.7% |
219,229
-871
| -0.4% | -$9.03K |
|
39
Incyte
INCY
$16.5B
| $2.12M | 0.66% |
34,110
+172
| +0.5% | +$10.7K |
|
40
Trevi Therapeutics
TRVI
$883M
| $2.12M | 0.66% |
885,924
| – | – |
|
41
Intellia Therapeutics
NTLA
$1.22B
| $2.07M | 0.64% |
50,858
+13,000
| +34% | +$530K |
|
42
Pliant Therapeutics
PLRX
$101M
| $1.94M | 0.6% |
107,267
+7,267
| +7% | +$132K |
|
43
Rhythm Pharmaceuticals
RYTM
$6.85B
| $1.92M | 0.59% |
+116,168
| New | +$1.92M |
|
|
CBAY
44
DELISTED
Cymabay Therapeutics
CBAY
| $1.75M | 0.54% |
+160,000
| New | +$1.75M |
|
|
AMAM
45
DELISTED
Ambrx Biopharma, Inc. Common Stock
AMAM
| $1.65M | 0.51% |
+100,000
| New | +$1.65M |
|
46
Cue Biopharma
CUE
$60M
| $1.47M | 0.46% |
403,402
+97,124
| +32% | +$355K |
|
|
CLYM
47
Climb Bio, Inc. Common Stock
CLYM
$151M
| $1.38M | 0.43% |
494,089
+8,134
| +2% | +$22.8K |
|
48
Annexon
ANNX
$226M
| $1.37M | 0.42% |
+389,911
| New | +$1.37M |
|
49
Zura Bio
ZURA
$133M
| $1.31M | 0.41% |
+160,000
| New | +$1.31M |
|
|
RETA
50
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $1.27M | 0.39% |
+12,500
| New | +$1.27M |
|